In the exploration of self-amplifying mRNA vaccines, such as ARCT-154 produced by Arcturus Therapeutics through their Japanese joint-venture Arcalis, the use of RNA viral RdRP for multiple replications of desired antigens like the spike protein has been discussed.
Concerns have been raised regarding the potential neutralization of such vaccines by treatments like the Zelenko Protocol, which includes zinc and RdRP inhibiting agents, possibly impacting the pharmaceutical industry's investment in mRNA vaccines.
Additionally, there's speculation that "Disease X" could be H5N1, with high fatality rates historically. Zinc supplementation, particularly with a potent zinc ionophore, is proposed as a strategy to mitigate replication of RNA viruses, including H5N1.
Now, attention is turned to the VEEV replicon (RdRP) backbone of ARCT-154, prompting further examination of its implications.
